Business Context and Reporting Period
Company: DDC Enterprise Limited (DDC)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: May 21, 2024
Context: The filing discloses receipt of a notice from NYSE Regulation regarding non-compliance with continued listing standards due to the failure to timely file the Annual Report on Form 20-F for the fiscal year ended December 31, 2023.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice regarding filing delinquency rather than a financial results report.
Material Changes and Delinquency Details
- Filing Delinquency: The Company failed to file its 2023 Form 20-F by the deadline of May 15, 2024.
- Reason for Delay: As previously disclosed in a Form 12b-25 filed on April 30, 2024, the delay resulted from difficulties in completing the financial statements for the Annual Report without unreasonable effort or expense.
- Listing Status: The Company received a notice on May 16, 2024, stating it is not in compliance with Section 1007 of the NYSE American Company Guide.
- Cure Period: The Company has an initial six-month cure period from the date of delinquency to file the overdue report and regain compliance.
Outlook, Risks, and Management Commentary
- Management Action: The Company is making all efforts to file the 2023 Form 20-F as soon as possible, aiming to complete it within the six-month Initial Cure Period.
- Delisting Risk: If the Company fails to file within the Initial Cure Period, the Exchange may grant an additional six-month cure period. Failure to file by the end of any applicable cure period will generally result in the commencement of suspension and delisting procedures.
- Discretionary Actions: The Exchange reserves the right to truncate cure periods or immediately commence delisting procedures if it deems continued listing inadvisable.
- Operations: The NYSE Notice does not affect the Company's business operations or its reporting obligations under SEC regulations. Class A Ordinary Shares will continue to be listed on NYSE American while the Company attempts to regain compliance.
Investor Verification Checklist
- Verify the exact deadline for the Initial Cure Period (six months from May 15, 2024).
- Monitor for the eventual filing of the 2023 Form 20-F to assess the severity of the financial statement delays.
- Watch for any further communications from NYSE Regulation regarding the truncation of cure periods or initiation of delisting procedures.
- Review the attached press release (Exhibit 99.1) for any additional details not summarized in the Form 6-K.